Agile therapeutics (nasdaq: agrx) upgraded to “buy” rating by analysts at maxim group

Princeton, nj / accesswire / september 28, 2023 / maxim group, a major investment bank, conducts and publishes stock analysis through its equity research team. the team has a strong reputation in the industry; a host of major firms use its research.
AGRX Ratings Summary
AGRX Quant Ranking